Xlife Sciences AG is a listed (m:access: XLS) Swiss company focusing on the performance and growth of promising technologies and therapies in the life sciences sector. With a track record of more than 28 years, we bridge the gap between research and development and healthcare markets. Together with universities or industrial partners we lead projects through the proof of concept phase after a successful invention disclosure. Throughout the last 28 years, the team has led 14 of 18 project companies successfully to an exit. We actively advise new innovations from the spin-off to the later out-licensing, trade sale or even, possibly an IPO. Long-term strategic partnerships, built on trust and transparency, form the basis of our success.
Xlife Sciences AG focuses on the early stage of the life sciences industry. A company in the biotech sector goes through the following phases: invention disclosure, preclinical phase (followed by phase 1, phase 2 and phase 3) and finally, the approval. Xlife Sciences AG invests intelligently in the first two phases: invention disclosure and the preclinical phase, and thus has a comparatively above average success rate for the biotech sector.